SERVICE INTRODUCTION
HEOR & HTA Support
Demonstrating the clinical and economic value of a medicine or healthcare technology has become increasingly important, if not mandatory. Economic analysis and outcomes research can be particularly challenging as HTA methodologies constantly evolve to meet the challenges of affordability.
Historically, budget impact and cost-effectiveness analysis have been used to support national reimbursement decisions, but they are of increasing interest to regional and local decision-makers, as well as budget-holders, such as hospital pharmacists.
But demonstrating value is more than economic analysis.
Early modelling can fine-tune market access strategy, as well as evidence generation planning by informing clinical trial design, literature reviews and real-world evidence planning.
CASE STUDY
Evidence gap analysis for a biologic treatment in severe atopic dermatitis
Our mid-sized pharma client had a new product in Phase 3 trials for severe atopic dermatitis. Demonstrating the product’s benefits versus lower-cost topical and oral treatments, and the severe burden of disease, was critical in order to justify the target price.
READ THE CASE STUDY HERE
WHERE WE FIT IN
Preparing for reimbursement
VALUE DEMONSTRATION & COMMUNICATION
We use modelling to identify pricing opportunities, or to quantify clinical trial endpoint thresholds for a product to be cost-effective. Closer to launch, we build budget impact models and link them to interactive communication tools.
We can identify the most appropriate solutions for your product and the challenges you face. We validate these key assumptions with clinicians and HTA advisors, while working alongside the functions in your organisation.
EVIDENCE GENERATION PLANNING
Early planning is always a good idea. Our team can build evidence development programmes early in phase 2, ensuring phase 3 trials meet HTA agencies’ needs. We can also lead you through the scientific advice processes offered by regulators and HTA organisations.
TESTING
Testing payer reactions to a target product profile, data or price point through primary research can determine whether a particular study is necessary to support access, for instance, or what evidence is needed to support sales volume assumptions.
HOW WE STAND OUT
We are flexible and pragmatic - we adapt our approach to your situation and needs. Our goal is to provide you with an actionable analysis to maximise your product's price and market access potential.
List of services
-
Developing market access and HTA strategies
-
Regulatory and HTA scientific advice
-
Evidence generation planning and gap analysis
-
Systematic and targeted literature reviews
-
Analogue analysis
-
Early economic modelling and budget impact models
-
Value communication tools – core value dossiers, payer value stories, value propositions
-
Payer and healthcare professional testing and primary research
-
Early assessment of price and access potential of pipeline and in-licensing opportunities.
CASE STUDY
Assessment of evidence gaps and support needs for a cystic fibrosis treatment
A medium-sized biotech company was developing a new product for cystic fibrosis indicated for the treatment of multiple disease genotypes, with varying levels of severity.
Our client wanted to conduct an evidence gap analysis and develop a support plan that captured the local needs and learnings from market access experience with their other cystic fibrosis products.